Oruka Therapeutics

Yahoo Finance • 20 days ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2... Full story

Yahoo Finance • last month

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 2 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics files to sell 39.43M shares of common stock for holders

* Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) has filed to sell 39,425,806 shares of common stock for holders. * This prospectus is not an offer to sell these securities. * Filing [https://seekingalpha.com... Full story

Yahoo Finance • 2 months ago

MoonLake rebounds despite downgrades prompted by trial setback

[Sign for Wall Street in New York City] Pharrel Wiliams MoonLake Immunotherapeutics (NASDAQ:MLTX [https://seekingalpha.com/symbol/MLTX]) traded higher on Tuesday even as Wall Street opted to downgrade the Swiss biotech following a late-st... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

[Clinical Drug Trials with inspiration and healthcare/medical concept on desk background] syahrir maulana/iStock via Getty Images Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) added ~20% in the premarket on Wedne... Full story

Yahoo Finance • 3 months ago

Oruka Therapeutics Reports Positive Interim Data From Phase 1 Study Of ORKA-001

(RTTNews) - Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers. ORKA-001, a long-acting monoclonal antibody targeting... Full story

Yahoo Finance • 3 months ago

Oruka Therapeutics Announces $180 Million Private Placement

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic ski... Full story

Yahoo Finance • 3 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated wi... Full story

Yahoo Finance • 4 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presen... Full story

Yahoo Finance • 4 months ago

Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug

Investing.com -- Oruka Therapeutics Inc (NASDAQ:ORKA) stock rose 6.6% after the company announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for a Phase 2a trial of ORKA-001... Full story

Yahoo Finance • 4 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics announces COO appointment

* Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) has promoted Laura Sandler to chief operating officer. * Sandler joined Oruka in 2024 as SVP of Operations and has over 20 years of experience in biopharma leade... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin d... Full story

Yahoo Finance • 6 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin di... Full story

Yahoo Finance • 6 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a... Full story

Yahoo Finance • 9 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity an... Full story

Yahoo Finance • 9 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differ... Full story

Yahoo Finance • 9 months ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin d... Full story